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Genes for peripheral tissue-restricted self-antigens are expressed in
thymic and hematopoietic cells. In thymic medullary epithelial cells,
self-antigen expression imposes selection on developing autoreactive
T cells and regulates susceptibility to autoimmune disease in mouse
models. Less is known about the role of self-antigen expression by
hematopoietic cells. Here we demonstrate that one of the endocrine
self-antigens expressed by human blood myeloid cells, proinsulin, is
encoded by an RNA splice variant. The surface expression of immu-
noreactive proinsulin was significantly decreased after transfection of
monocytes with small interfering RNA to proinsulin. Furthermore,
analogous to proinsulin transcripts in the thymus, the abundance of
the proinsulin RNA splice variant in blood cells corresponded with the
length of the variable number of tandem repeats 5 of the proinsulin
gene, known to be associated with type 1 diabetes susceptibility.
Self-antigen expression by peripheral myeloid cells extends the um-
brella of ‘‘immunological self’’ and, by analogy with the thymus, may
be implicated in peripheral immune tolerance.
variable number of tandem repeats  insulin  type 1 diabetes 
siRNA  self-antigen
T cells with high-avidity receptors for self-antigens are deleteddevelopmentally in the thymus. This central mechanism of
immune tolerance appears to depend on the ectopic expression
of self-antigens by thymic medullary epithelial cells (1–4).
However, in both the mouse (5) and human (6, 7) thymus,
self-antigen RNA transcripts or peptide epitopes are also ex-
pressed by cells bearing markers of dendritic and monocytic
antigen-presenting cells. In human thymus and spleen (6), and
more recently in human blood (8), Pugliese and colleagues have
described cells with myeloid lineage markers that stain with
antibodies to the pancreatic  cell autoantigens in type 1 diabetes
[i.e., proinsulin, glutamic acid decarboxylase (GAD), and ty-
rosine phosphatase-like insulinoma antigen (IA-2)] and tran-
scribe the proinsulin gene. Hematopoietic progenitor cells have
been shown to transcribe genes and express proteins for several
neural autoantigens, including myelin basic protein (9) and
GAD65 (10), and bone marrow-derived cells in extra-pancreatic
tissues have been reported to express genes for pancreatic
hormones (11). A role for ectopic self-antigen expression in
hematopoietic cells was suggested by Zheng et al. (12), who
demonstrated activation-induced death of self-reactive T cells in
response to bone marrow cells expressing self-antigen.
Proinsulin is a key autoantigen that drives pancreatic  cell
destruction in type 1 diabetes (13). In the human thymus, proinsulin
mRNA abundance correlates with allelism of the variable number
of tandem repeats (VNTR) upstream of the proinsulin coding
region on chromosome 11 (14, 15), identified as the IDDM2
susceptibility locus for type 1 diabetes (16, 17). In addition to
abundance of expression, the nature of self-antigen in lymphoid
tissues may be important for the acquisition of immune tolerance.
For example, Klein et al. (18) found that thymic expression of
proteolipid protein (PLP), the major myelin sheath protein and an
autoantigen in experimental autoimmune encephalomyelitis, was
mainly restricted to a shorter RNA splice variant that did not
encode the neuronal peptide recognized by T cells in susceptible
mice. Similarly,Diez et al. (19) found that human thymus and spleen
exclusively expressed a shorter RNA splice variant of IA-2 lacking
the exon that in pancreatic  cells encodes the dominant autoan-
tigenic peptide in type 1 diabetes. Thus, the differential expression
of self-antigen in lymphoid tissues could educe an autoimmune T
cell repertoire selectively directed against extralymphoid tissues.
Central tolerance is not absolute, and self-reactive T cells (e.g.,
to proinsulin and GAD) can be readily detected in the peripheral
blood of healthy individuals (20). The mechanisms that avert
activation of peripheral self-reactive T cells and prevent autoim-
mune disease, namely T cell deletion, T cell anergy, and the
induction of regulatory T cells, depend classically on the uptake and
presentation of self-antigens by specialized antigen-presenting den-
dritic cells (21). Extrapolating from the thymic paradigm, however,
self-antigens could also be expressed constitutively by peripheral
cells with antigen-presenting properties. Here we demonstrate that
endocrine self-antigens expressed by human blood myeloid cells
include an immunoreactive epitope for proinsulin encoded by an
RNA splice variant of the proinsulin gene, the abundance of which
corresponds with the length of the proinsulin VNTR.
Results
Blood Myeloid Cells Express Proinsulin and Other Self-Antigens. A
subpopulation of live-gated peripheral blood mononuclear cells
(PBMC) was delineated with monoclonal antibodies (mAbs) spe-
cific for proinsulin, GAD, 21-hydroxylase (21-OH), glucagon, or
somatostatin, in all samples obtained from 15 healthy individuals
(Fig. 1).Dual color staining revealed that proinsulin andGADwere
coexpressed by the same cells (Fig. 1 Lower Right). The proinsulin
mAb we used, GS9A8, recognizes the threonineserinearginine
residues at the junction of the insulin B chain and the connecting
(C) peptide in proinsulin (22). Cells were also stained with mAb
KL1 to the B–C junction in proinsulin but not with mAb 2B7 that
recognizes a conformational epitope comprising the N- and C-
terminal regions of C-peptide (data not shown).
Cells staining for proinsulin displayed markers of dendritic
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cells (CD11c, CD1a) and monocytemacrophages (CD11c,
CD14) but not of T cells (CD3), B cells (CD19), or NK cells
(CD56) (Fig. 2a). Analysis of blood dendritic cell subsets re-
vealed that proinsulin was preferentially expressed by CD11c
myeloid rather than by CD123 plasmacytoid dendritic cells
(Fig. 2b). No staining was observed with three different isotype
control mAbs, and blocking of Fc receptors by the addition of
pooled mouse serum and human IgG had no effect on the
staining of cells by mAbs to proinsulin or GAD.
To further define the specificity of proinsulin expression, PBMC
were FACS-sorted into cells either positive or negative for the
myeloid marker, CD11c. The cells were then lysed in 8% SDS,
spotted onto nitrocellulose membrane, and immunoblotted with
proinsulin mAb KL1 (Fig. 2c). Proinsulin immunoreactivity was
observed predominantly in CD11c cells. By densitometric com-
parison with serial dilutions of proinsulin (Fig. 2), the number of
proinsulin-equivalent binding sites per CD11c cell was estimated
to be on the order of 60,000.
A small amount of proinsulin is cosecreted with insulin from the
pancreatic  cell. Proinsulin has a low affinity for the insulin
receptor, and binding sites specific for proinsulin itself have been
described on lymphocytes (23). To exclude any contribution of
exogenous proinsulin to the staining observedwith proinsulinmAb,
we studied four individuals with long-standing type 1 diabetes and
undetectable circulating immunoreactive proinsulinC-peptide. The
proportion of these patients’ PBMC that stained with proinsulin
mAbGS9A8 (22.6%, 22.0%, 16.0%, and 14.9%) was similar to that
of age- and sex-matched healthy controls (23.5%, 13.8%, 21.7%,
and 22.6%), indicating that staining was not due to the uptake of
circulating proinsulin preferentially onto myeloid cells.
Blood Cells Transcribe Self-Antigen Genes, Including a Proinsulin RNA
Splice Variant. RNA was extracted from PBMC, and RT-PCR was
performed with intron-spanning nested primer sets (see Table 1,
which is published as supporting information on the PNAS web
site). cDNA could be amplified for proinsulin, GAD65, and 21-OH
in each of five healthy individuals examined (example shown in Fig.
3a), and product specificity was confirmed by DNA sequencing.
Real-time PCR was then used to compare the expression of
proinsulin transcripts between human pancreas, thymus, and spleen
and PBMCand of 21-OH transcripts between human adrenal gland
and PBMC. Amplicon-specific hybridization probes were used to
quantify PCR product by fluorescence resonance energy transfer.
PCR-amplified proinsulin or 21-OH cDNAs were standardized
against the low copy number porphobilinogen deaminase (PBGD)
housekeeping gene and expressed as a proportion of titrated
pancreatic proinsulin or adrenal 21-OH DNA, respectively. The
abundance of proinsulin transcripts in thymus, spleen, and PBMC
Fig. 1. A subpopulation of blood mononuclear cells expresses epitopes for
endocrine self-antigens. PBMC purified from healthy individuals were labeled
with FITC-conjugated mAbs to proinsulin (GS9A8), GAD65 (GAD6), 21-OH 1,
glucagon, or somatostatin and with isotype control antibodies (thin lines in
the histogram plots) and analyzed by flow cytometry. Dead cells were iden-
tified by propidium iodide nuclear staining and excluded from the analysis.
The Lower Right plot shows labeling of the same cell population by biotin
(streptavidin-PE)-conjugated antibody to proinsulin and FITC-conjugated an-
tibody to GAD65. The data shown are representative of 15 individuals studied.
Fig. 2. Myeloid lineage cells express an epitope for proinsulin. (a) PBMC purified from healthy individuals were labeled with PE-conjugated mAbs to T cell (CD3),
B cell (CD19), NK cell (CD56), dendritic cell (CD11c, CD1a), and monocytemacrophage cell (CD11c, CD14) markers and with FITC-conjugated mAb (GS9A8) to
proinsulin and analyzed by flow cytometry. Binding of isotype control antibodies is represented by the shaded histograms. (b) Dendritic cells were purified from
buffy coat-derived PBMC as described in Materials and Methods, labeled with markers of myeloid (HLA-DR, CD1c) or plasmacytoid (HLA-DR, CD123) dendritic
cell subsets and with FITC-conjugated antibody (GS9A8) to proinsulin, and analyzed by flow cytometry. (c) FACS-sorted CD11c and CD11c PBMC (each 5 106
per milliliter) were solubilized in 8% SDS and spotted onto nitrocellulose membrane, in parallel with serial dilutions of recombinant human proinsulin, and
immunoblotted with the antiproinsulin mAb KL1.
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was 0.01–0.1% of that in pancreas; the abundance of 21-OH
transcripts in PBMCwas0.05% of that in adrenal gland (data not
shown).
The amount of proinsulin mRNA detected was low relative to
immunoreactive proinsulin. Others have reported RNA splice
variants for self-antigens in the thymus (18, 19) and for proinsulin
in the pancreas (24). Therefore, we looked for proinsulin splice
variants in lymphoid tissues and PBMC. The human preproinsulin
gene comprises three exons and two introns and, because the start
codon is in exon 2, exon 1, intron 1, and part of exon 2 are in the
5 untranslated region. A variant splice site was reported for
pancreatic proinsulin in intron 1 (24). We designed a 5 forward
primer (Table 1) that crosses the variant splice site and does not
amplify native proinsulin or genomic DNA. By using this primer
and the 3 reverse primers andhybridization probes used to quantify
expression of native proinsulin, we detected the pancreatic proin-
sulin splice variant in human thymus, spleen, and PBMC. Themean
percentage ( SD) of the splice variant in PBMC from 29 fasting,
healthy individuals was 1.38  0.94 of that in the pancreas. To
compare the relative amounts of native and splice variant RNAs
and at the same time demonstrate correspondence between cell
surface immunoreactive proinsulin and proinsulin gene transcrip-
tion, we sorted proinsulin mAb GS9A8 and GS9A8 cells from
PBMC for RNA extraction and real-time PCR. Compared with
native proinsulin transcripts, splice variant transcripts were more
abundantly expressed in GS9A8 cells and were not detected in
GS9A8 cells (Fig. 3b). Although the splice variant was the minor
transcript in the pancreas, it was the major transcript in proinsulin
mAb-positive blood cells, being 20-fold more abundant than the
native transcript.
Introduction of Proinsulin Small Interfering RNA (siRNA) Reduces Expres-
sion of Immunoreactive Proinsulin. To confirm the specificity of
immunoreactive proinsulin on myeloid cells, adherent monocytes
were transfected with siRNAs to the second exon of insulin or with
control siRNA. Cells were then incubated for 48 h and analyzed by
flow cytometry for expression of proinsulin or GAD65. The num-
bers of proinsulin- or GAD65-positive cells and their mean fluo-
rescence intensities were no different after mock transfection or
after transfection with the control siRNA (Fig. 4). However,
compared with mock or control transfections, transfection with the
targeted siRNA3 reduced the number of immunoreactive proin-
sulin-expressing cells (Fig. 4 Upper Right). Results were expressed
as the percentage of cells positive for immunoreactive proinsulin or
GAD relative to the mock transfection. Themaximum reduction in
each of three separate experiments (63%, 65%, and 70%) was seen
at 500 nM siRNA (P 0.03; one-way ANOVA). Transfection with
proinsulin-targeted siRNAs had no effect on the expression of
immunoreactive GAD.
Proinsulin mRNA Splice Variant Expression Corresponds with the Length
of the VNTR at the INS Susceptibility Locus for Type 1 Diabetes.The INS
or IDDM2 susceptibility locus for type 1 diabetes maps to a VNTR
5 of the proinsulin gene coding region (16, 17). The short (class I)
VNTR allele is associated with less thymic proinsulin mRNA (14,
15) and a higher risk for type 1 diabetes (17), whereas the long (class
Fig. 3. Blood cells transcribe self-antigen genes, including a proinsulin RNA splice variant. (a) RNA was freshly isolated from PBMC, reverse-transcribed into
cDNA with random hexamer oligonucleotides, and amplified by PCR using nested sets of sequence-specific primers that spanned introns to avoid amplifying
genomic DNA. GAPDH was used as a housekeeping gene. Electrophoresis in 1% agarose and staining with ethidium bromide demonstrated cDNAs for proinsulin,
GAD65, and 21-OH in all five individuals examined (one example shown). Product identities were confirmed by DNA extraction and sequencing. (b) Native (N)
and splice variant (SV) proinsulin RNAs from the pancreas and flow-sorted PBMC were quantified by real-time PCR (Upper), and the PCR products were identified
by staining with ethidium bromide after electrophoresis in 1% agarose (Lower).
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III) allele is associated with more thymic proinsulin mRNA and a
lower risk for type 1 diabetes. Genotyping for the 23 Hph I
polymorphism, the alleles of which are in linkage disequilibrium
with the class I and III alleles, was performed on 28 healthy subjects
in whom the expression of the proinsulin mRNA splice variant in
PBMC was measured by real-time PCR. Consistent with the
reported allele frequencies (25), only 2 of the 28 subjects were class
IIIIII. The class II genotype was associated with lower expression
of proinsulin mRNA splice variant in PBMC (median  1.33% of
pancreas, n  20) compared with the class IIII genotype (me-
dian  2.11% of pancreas, n  6) (P  0.03, unpaired t test with
Welch correction).
Discussion
We show that the proinsulin gene is transcribed preferentially as an
RNA splice variant by human blood myeloid cells, which express
immunoreactive proinsulin and epitopes for other self-antigens.
Proinsulin detected on myeloid cells was not due to the uptake of
circulating proinsulin. All nucleated cells have receptors for insulin
that bind proinsulin with low affinity, and lymphocytes have been
reported to have specific receptors for proinsulin (23), but we did
not observe staining of T or B lymphocytes with mAbs to proin-
sulin. Furthermore, proinsulin staining was similar in healthy
controls and individuals with type 1 diabetes who had undetectable
circulating proinsulin C-peptide. Importantly, we found a direct
correspondence in sorted cells between proinsulin gene transcrip-
tion and surface immunoreactive proinsulin, and the latter was
specifically reduced by the introduction of insulin-specific siRNAs.
The relatively high expression of proinsulin immunoreactivity
compared with native proinsulin mRNA prompted us to search for
proinsulin mRNA splice variants. The splice variant we identified
was reported by Shalev et al. (24) as a minor transcript in human
pancreas, but in peripheral blood cells it appears to be the major
transcript. It is more efficiently translated than the native gene (24),
which may allow for even greater expression of proinsulin protein.
Because splicing is initiated in the 5 untranslated region, the
variant RNA encodes full-length proinsulin protein and could
therefore generate epitopes recognized by antibodies raised to the
native protein. In contrast to splice variants of the autoantigens PLP
(18) and IA-2 (19), which encode truncated proteins in the thymus
but full-length proteins elsewhere, the proinsulin splice variant
would not obviously lead to different forms of proinsulin protein
being expressed in myeloid cells and pancreatic  cells. However,
alternate splicing may serve as a mechanism for ectopic expression
of proinsulin, which otherwise would only be expressed in  cells
with their specialized transcriptional machinery.
Self-antigen expression by thymic medullary epithelial cells is
considered to be a requirement for the negative selection and
deletion of high-affinity, self-reactive T cells (3, 4). Several inves-
tigators have also reported self-antigen transcription and protein
expression by cells with dendritic and monocytic phenotypes in the
mouse and human thymus (5–7) and in the periphery (8–12). The
mAbs we used to detect proinsulin are to the B–C chain junction,
which appears to be an important immunogenic region in proin-
sulin. Most of the available mouse mAbs to proinsulin recognize
this region, which comprises a T cell epitope in autoimmune
diabetes-prone nonobese diabetic (NOD) mice (26, 27) and hu-
mans at risk for type 1 diabetes (13, 28). In the NOD mouse, an
epitope spanning the B–C junction binds to I-Ag7, the MHC class
II molecule, and induces regulatory, antidiabetogenic CD4 T cells
when administered to the nasorespiratory mucosa (27). On the
other hand, we cannot exclude the possibility that other regions of
proinsulin are also accessible on the surface of myeloid cells,
including other epitopes implicated in the pathogenesis of autoim-
mune diabetes in humans (29, 30) and NOD mice (31). How
proinsulin or proinsulin peptide is ‘‘presented’’ onmyeloid cells, and
the role of peripheral self-antigen expression in immune homeosta-
sis, are key questions to be addressed.
Proinsulin is a dominant autoantigen driving cell destruction by
autoreactive T cells in type 1 diabetes (13). Previously, we reported
that syngeneic transplantation of hematopoietic stem cells encoding
proinsulin completely prevents autoimmune diabetes in NODmice
(32), an effect most likely mediated by the expression of proinsulin
in resting dendritic cells in peripheral lymphoid tissues (33). In the
present study, we found a relationship between the abundance of
proinsulin mRNA splice variant expression in circulating cells and
the length of the INS VNTR (IDDM2 susceptibility locus). The
same relationship has been reported for native proinsulin RNA in
Fig. 4. Introduction of proinsulin siRNA reduces expression of immunoreactive proinsulin. As described inMaterials andMethods, PBMC (5 106 per milliliter)
in RPMI medium 1640 containing 10% FCS were incubated in uncoated plastic flasks in 5% CO2air at 37°C for 3 h. Adherent cells (5  106) were resuspended
in transfection medium for human monocytes with or without (‘‘mock transfection’’) 500 nM siRNA and transfected. Cells, including some not transfected, were
then incubated in transfection medium for human monocytes in 5% CO2air at 37°C for 48 h. After washing and the addition of FcR blocking reagent, cells were
stained with KL1-FITC (proinsulin) (Upper) or biotinylated-GAD6-streptavidin-PE (GAD65) (Lower) and HLA-DR-APC mAbs or isotype control mAbs and analyzed
by flow cytometry. siRNA1–siRNA3 are to the second exon of insulin; the ve siRNA, used as a negative control, is a scrambled version of siRNA1.
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the human thymus (14, 15). The shorter (class I) allele, which is
associated with a greater risk of type 1 diabetes than the longer
(class III) allele (17), corresponds with a lower abundance of
proinsulin RNA splice variant in the thymus. In the mouse thymus,
a lower abundance of proinsulin RNA was associated with higher
peripheral T cell reactivity to proinsulin (34). These observations
lend weight to the hypothesis that type 1 diabetes susceptibility
reflects the degree to which proinsulin-reactive T cells are edited in
the thymus, as determined by the VNTR allele-regulated level of
proinsulin gene transcription. Therefore, the association we de-
scribe between the VNTR alleles and peripheral expression of the
proinsulin RNA splice variant could also contribute to the main-
tenance of antigen-specific tolerance. In humans, this potential
mechanism of tolerance can now be directly investigated in periph-
eral blood. ‘‘Immunological self’’ may extend from a static popu-
lation of thymic medullary epithelial cells to circulating, bone
marrow-derivedmyeloid cells, linking central thymic and peripheral
tolerance.
Materials and Methods
Human Tissues. Heparinized venous blood was obtained, after an
overnight fast, from 28 healthy, young adult individuals and 4 young
adults who had had type 1 diabetes for a median duration of 9.2
years. Fresh white cell buffy coats were provided by the Australian
Red Cross with Human Ethics Committee approval and informed
consent. PBMCwere isolated by density centrifugation over Ficoll–
Hypaque Plus (Amersham Biosciences, Castle Hill, Australia).
Human pancreas tissue was obtained from organ donor subjects
with Human Ethics Committee approval. Total RNA from human
thymus, spleen, and adrenal gland was purchased from Becton
Dickinson (North Ryde, Australia).
C-Peptide Assay. Plasma immunoreactive C-peptide was mea-
sured with the Immulite 2000 system (Diagnostics Products, Los
Angeles, CA).
Antibodies. Themouse mAb, clone GS9A8, recognizes the junction
between insulin B chain and the connecting (C) peptide in human
proinsulin (22).AmousemAb specific for a conformational epitope
comprising the N- and C-terminal regions of human C-peptide
separated by a  turn at position 47–50 of proinsulin (clone 2B7)
was purchased fromAdvanced Immunochemical (White City, CA).
Mouse mAbs to human proinsulin were also generated in the
Monoclonal Antibody Laboratory of The Walter and Eliza Hall
Institute. An IgG1 clone, termed KL1, was used in the current
study. Epitope mapping with overlapping synthetic peptides span-
ning the full length of human proinsulin revealed that precipitation
of 125I-proinsulin by KL1 was blocked by proinsulin B24-C36
(FFYTPKTRREAED). Thus, the KL1 epitope, similarly to clone
GS9A8, spans the B–C chain junction of proinsulin.
GAD6, a mouse IgG2a mAb that reacts with human GAD65, an
autoantigen in type 1 diabetes, was a gift of David Gottlieb
(Washington University School of Medicine, St. Louis, MO).
21-OH 1, a mouse IgG mAb to human 21-OH, an autoantigen in
Addison’s disease, was a gift of RSRLtd (Cardiff, U.K.). IgGmAbs
to somatostatin and glucagon were purchased from Novo Biolabs
(Bagsvaerd, Denmark). Antibodies to proinsulin and other self-
antigens were either conjugated to fluorescein isothiocyanate
(FITC) or biotinylated for use with streptavidin-fluorochromes.
Phycoerythrin (PE)-conjugated antibodies toCD11c, CD14, CD1a,
CD3, CD19, and CD56, and PerCP, or APC-conjugated antibodies
to HLA-DR and CD45, were purchased from BD PharMingen
(PaloAlto, CA). PE-conjugated antibodies toCD1c (BDCA-1) and
CD123 were purchased from Miltenyi Biotec (North Ryde, Aus-
tralia). FITC- or PE-conjugated IgG1 clone MOPC (Becton Dick-
inson, Mountain View, CA), FITC-conjugated IgG1 clone OX6
and IgG2a clone 10.2.16, and nonconjugated IgG1 clone 2D6,
produced in our mAb facility, were used as isotype controls.
Proinsulin. Recombinant human proinsulin was expressed in Esch-
erichia coli, extracted and refolded, and purified to homogeneity by
HPLC-mass spectrometry in collaboration with Kaku Nakagawa
(Kaneka Corporation, Takasago, Japan). Recombinant GAD65
was a gift of Peter Van Endert (Hoˆpital Necker, Paris, France).
Flow Cytometry. Flow cytometry was performed on freshly isolated
PBMC or onmonocytes that had been transfected with siRNAs (as
described below). PBMC were washed and suspended at a con-
centration of 106 per milliliter in 100 l of FACS buffer (1% FCS
in PBS) containing 10 l of pooled BALBc mouse serum and 10
l of pooled human IgG to block binding of mouse antibody to
human Fc receptors and were stained with a 2gml concentration
of primary antibody for 30 min on ice. Nonfluorochromated mAbs
to 21-OH, somatostatin, and glucagon were detected by using
FITC-conjugated F(ab)2 affinity-purified sheep anti-mouse anti-
bodies (Chemicon, Victoria, Australia); in these experiments,
mouse serum was not used for blocking the primary antibody, and
10l of sheep serumwas used to block the secondary antibody. The
cells were washed with cold FACS buffer and then analyzed.
Analyses were performed on a FACScan (Becton Dickinson) after
exclusion of propidium iodide-labeled dead cells, and data were
analyzed with CellQuest software (Becton Dickinson).
Cell Sorting and Dendritic Cell Purification. Healthy donor PBMC
labeled with FITC-labeled GS9A8 or KL1 mAb to proinsulin and
with PE-labeledmAb to CD11c were sorted in aMoFlo high-speed
FACS sorter (DakoCytomation, Fort Collins, CO) to a purity
85%. Lineage-negative CD4 dendritic cells were purified from
buffy coat-derived PBMC with a blood dendritic cell isolation kit
(Miltenyi Biotec) and further depleted on the MoFlo sorter of
lineage-positive cells labeled with PE-conjugated antibodies to
CD3, CD19, CD14, and CD56. Dendritic cells were then identified
by staining for HLA-DR and either CD11c (myeloid) or CD123
(plasmacytoid) markers.
Cell Lysis and Immunoblotting. PBMC were FACS-sorted into
CD11c andCD11c cells, and equal numbers (5 105) were lysed
directly in 100 l of 125 mM Tris containing 8% SDS, 0.1 M DTT,
and 10% glycerol for 10min at 22°. After centrifugation at 10,000
g for 10 min, supernatants were spotted in parallel onto nitrocel-
lulose membrane and immunoblotted with biotinylated KL1 mAb
detected with streptavidin-HRP. Dilutions of known amounts of
humanproinsulinwere immunoblotted in parallel for densitometric
comparison to estimate the proinsulin equivalents expressed per
cell.
RNA Isolation and cDNA Synthesis. RNA was isolated using an
RNeasy Mini Kit (Qiagen, Clifton Hill, Australia). RNA integrity
was confirmed by spectrophotometry at 260280 nmand inspection
of 28S and 18S band intensities after agarose gel electrophoresis.
Total RNA (1g) was reverse-transcribed into cDNAwith random
hexamer primers (Promega, Annandale, Australia) and Moloney
murine leukemia virus (MMLV) reverse transcriptase (Promega)
in the presence of RNAsin (Promega). cDNA samples were ali-
quoted and stored at 20°C.
PCR.Nested PCRwas performed in 50l of PCR buffer containing
final concentrations of 200 nM primers, 2 mM MgCl2, 400 M
dNTPs, 5 units of TaqDNA polymerase, and 125 ng of cDNA
template. After 35 cycles of amplification in a FTS-960 thermal
cycler (CorbettResearch,Mortlake,Australia), 2l of the PCRwas
used as DNA template for a further 35-cycle PCR performed with
nested primers. Primers (Table 1) were purchased from Sigma
Genosys (Woodlands, TX) and usually spanned introns to avoid
amplification of contaminating genomicDNA.A 5 forward primer
was designed to detect the proinsulin splice variant identified by
Shalev et al. (24) in human pancreatic islets. Splicing is initiated in
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intron 1 upstream of the normal start codon in exon 2, retaining 26
bp of intron 1 without altering the coding region. The identity of
amplified PCR product was confirmed by electrophoresis in 1%
agarose gel, band extraction with the QIAquick gel extraction
method (Qiagen), and sequencing by BigDye TerminatorReaction
(Applied Biosystems, Scoresby, Australia).
Real-time PCR was performed in a Lightcycler (Roche Diag-
nostics, Castle Hill, Australia) with sequence-specific hybridization
probes (Table 1) and the QuantiTect probe kit (Qiagen). Master
mixtures were prepared in accordance with the manufacturer’s
instructions to include a 0.5 M concentration of each primer and
a 0.1 M concentration of each probe. Water-only samples were
used as negative controls. Amplification for all primerprobe sets
was carried out with initial activation for 15 min at 95°C ramped at
20°Csec, followed by 45 cycles each of denaturation at 95°C for 10
sec, annealing at 50°C for 30 sec, and extension at 72°C for 30 sec,
ramped at 20°Csec. PCR products were verified by 1% agarose gel
electrophoresis. PBGDwas chosen as a housekeeping gene because
it has no known pseudogenes and is stably expressed at a low copy
number. Sequence-specific standard curves were generated for
PBGD, proinsulin, proinsulin splice variant, and 21-OH by using
serial dilutions of PBMC, thymus, spleen, and pancreas or adrenal
cDNA. The expression of product with respect to pancreas or
adrenal DNA, each normalized to 100%, was calculated with the
Lightcycler RelQuant software (Roche Diagnostics).
Proinsulin Expression After Introduction of siRNA. Three annealed
siRNAs to the second exon of proinsulin (siRNA1–siRNA3) and an
siRNA consisting of the scrambled sequence of siRNA1 lacking
homology to any known gene (negative control) (see Table 2, which
is published as supporting information on the PNAS web site) were
purchased from Ambion (Austin, TX) at a stock concentration of
100M.PBMC(5 106 permilliliter) in completemedium (RPMI
medium 16401 mM sodium pyruvate0.05 mM 2-mercaptoetha-
nol0.1 mM nonessential amino acids10% FCS2 mM glutamine)
were incubated in uncoated plastic flasks in a humidified atmo-
sphere of 5% CO2air at 37°C for 3 h. After gentle decanting of
nonadherent cells, the adherent monocytes were collected by
scraping, washed in medium, and counted. Then, 5 106 cells were
resuspended in 100l Amaxa nucleofection solution formonocytes
(HumanMonocyte Nucleofector Kit; Amaxa Biosystems, Cologne,
Germany) containing up to 500 nM siRNA and transfected in an
Amaxa nucleofector electroporator on program T-08, in accor-
dance with the manufacturer’s instructions. The cells were imme-
diately mixed with 500 l of prewarmed human monocyte nucleo-
fector medium, transferred into 24-well plates containing 1 ml of
thismediumperwell, and incubated in 5%CO2air at 37°C for 48 h.
After collection and washing in complete medium and the addition
of FcR blocking reagent (Miltenyi Biotec) for 10 min at 4°C, cells
were stained with FITC-KL1 (proinsulin) or FITC-GAD (GAD65)
and APC HLA-DR mAbs or isotype control mAbs in parallel
samples and analyzed by flow cytometry. Compensations were
performed before addition of propidium iodide to the samples.
INS VNTR Genotyping. The INS gene23Hph I AT polymorphism
shows association with type 1 diabetes susceptibility and is in strong
linkage disequilibriumwith other susceptibility alleles, including the
VNTR polymorphism upstream of the INS gene (16, 17). The23
Hph I site was genotyped after PCR with 10 pmol of the primers
(5–3) AGCAGGTCTGTTCCAAGG and CTTGGGTGTGTA-
GAAGAAGC in a 10-l reaction containing 1.0 l of 1 mM
dNTPs, 0.6 l of 25 mMMgCl2, 0.5 units of Taq polymerase, 10%
glycerol, and 100 ng of genomic DNA. The PCR was performed in
a CR-9600 cycler (Corbett Research) at 94°C for 3min, followed by
30 cycles of 94°C for 30 sec, 60°C for 30 sec, and 72°C for 30 sec and
a final cycle of 72°C for 5 min. The PCR product was digested for
2 h at 37°C in a 20-l reaction containing 12 l pf dH2O, 5 l of
PCR product, 2l of Hph I 10 buffer, and 1 unit of Hph I. Under
these conditions, the A allele was indicated by the presence of a
120-bp band and the T allele by a 171-bp band.
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